Vivo Capital LLC reduced its stake in DBV Technologies S.A. (NASDAQ:DBVT - Free Report) by 97.6% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 32,020 shares of the company's stock after selling 1,322,417 shares during the quarter. Vivo Capital LLC owned about 0.16% of DBV Technologies worth $99,000 as of its most recent SEC filing.
Wall Street Analyst Weigh In
A number of research firms recently issued reports on DBVT. StockNews.com started coverage on shares of DBV Technologies in a research note on Wednesday. They issued a "hold" rating on the stock. JMP Securities reiterated a "market outperform" rating and issued a $10.00 price objective on shares of DBV Technologies in a report on Friday, January 10th.
Read Our Latest Stock Analysis on DBVT
DBV Technologies Stock Performance
Shares of DBVT traded down $0.37 during mid-day trading on Friday, hitting $8.53. 73,375 shares of the company's stock were exchanged, compared to its average volume of 183,152. The stock's 50-day moving average is $5.91 and its 200-day moving average is $4.47. DBV Technologies S.A. has a fifty-two week low of $2.20 and a fifty-two week high of $9.59. The company has a market cap of $175.48 million, a price-to-earnings ratio of -1.90 and a beta of -0.08.
DBV Technologies (NASDAQ:DBVT - Get Free Report) last issued its quarterly earnings results on Friday, April 11th. The company reported ($1.10) earnings per share for the quarter. DBV Technologies had a negative return on equity of 106.07% and a negative net margin of 815.73%. The company had revenue of $0.51 million for the quarter. As a group, equities research analysts anticipate that DBV Technologies S.A. will post -7.05 EPS for the current year.
DBV Technologies Profile
(
Free Report)
DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.
Featured Articles
Before you consider DBV Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DBV Technologies wasn't on the list.
While DBV Technologies currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
